Rob Fiorentino

Rob Fiorentino, MD, MPH is the VP Clinical Development at Kate Therapeutics since January 2022. Prior to that, Rob served as Senior Director, Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson from September 2019 to January 2022. Rob also held the position of Senior Director, Clinical Research & Development at REGENXBIO Inc. from May 2015 to September 2019, where Rob led clinical development teams for gene therapy programs. Earlier in their career, Rob worked at the FDA in various roles including Medical Team Leader in the Division of Gastroenterology and Inborn Errors Drug Products. Dr. Fiorentino holds a MPH from Harvard T.H. Chan School of Public Health and an MD from New York Medical College.